JPMorgan Chase & Co. Sells 4,307 Shares of Amedisys, Inc. (NASDAQ:AMED)

JPMorgan Chase & Co. lessened its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 4.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 84,329 shares of the health services provider’s stock after selling 4,307 shares during the period. JPMorgan Chase & Co.’s holdings in Amedisys were worth $8,139,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. KBC Group NV acquired a new position in Amedisys during the 3rd quarter worth $63,000. Signaturefd LLC lifted its position in shares of Amedisys by 20.9% during the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock worth $132,000 after purchasing an additional 236 shares during the last quarter. CWM LLC boosted its stake in Amedisys by 14.5% during the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock valued at $211,000 after purchasing an additional 277 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Amedisys in the 3rd quarter valued at approximately $243,000. Finally, Intech Investment Management LLC bought a new position in Amedisys in the 2nd quarter worth approximately $280,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Up 0.0 %

AMED opened at $91.98 on Wednesday. The business has a 50 day moving average of $89.42 and a 200-day moving average of $94.44. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.50, a P/E/G ratio of 1.84 and a beta of 0.72. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The company had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. During the same period last year, the company earned $0.98 earnings per share. Amedisys’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Amedisys, Inc. will post 4.45 earnings per share for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.